GB1211 (Selvigaltin) Combination Therapy

Phase I Trial of GB1211 (Selvigaltin), an Oral Galectin-3 (Gal-3) Inhibitor, Combined With Standard of Care Treatment in Relapsed/Refractory Multiple Myeloma (RRMM)

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1
Enrollment
21 patients (estimated)
Sponsors
Roswell Park Cancer Institute
Trial Type
Treatment
Last Update
2 days ago
SparkCures ID
2147
NCT Identifier
NCT07082270

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.